<SEC-DOCUMENT>0001493152-19-019606.txt : 20200225
<SEC-HEADER>0001493152-19-019606.hdr.sgml : 20200225
<ACCEPTANCE-DATETIME>20191223152626
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001493152-19-019606
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20191223

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protagenic Therapeutics, Inc.\new
		CENTRAL INDEX KEY:			0001022899
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-BUSINESS SERVICES, NEC [7389]
		IRS NUMBER:				061390025
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		149 FIFTH AVENUE
		STREET 2:		SUITE 500
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10010
		BUSINESS PHONE:		(212) 994-8200

	MAIL ADDRESS:	
		STREET 1:		149 FIFTH AVENUE
		STREET 2:		SUITE 500
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10010

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Atrinsic, Inc.
		DATE OF NAME CHANGE:	20090630

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NEW MOTION, INC.
		DATE OF NAME CHANGE:	20070504

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MPLC, Inc.
		DATE OF NAME CHANGE:	20050608
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="logo_001.jpg" ALT="Description: Description: Macintosh HD:Users:alexarrow:Dropbox:Protagenic Therapeutics:PTI Operations:PTI Logo.jpg" STYLE="height: 84px; width: 214px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">149
Fifth Ave, Suite 500</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, NY 10010</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
23, 2019</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>VIA
EDGAR TRANSMISSION</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anthony
Watson</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Division
of Corporation Finance</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office
of Trade &amp; Services</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
Securities and Exchange Commission</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Division
of Corporation Finance</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Washington,
D.C. 20549</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 15%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RE:</FONT></TD>
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Protagenic
    Therapeutics, Inc.</B></FONT></TD>
    <TD STYLE="width: 30%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form
    10-K for the Fiscal Year Ended December 31, 2018</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filed
    March 29, 2019</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>File
    No. 000-51353</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Mr. Watson:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
am the Chief Financial Officer of Protagenic Therapeutics, Inc. (the &ldquo;<U>Company</U>&rdquo;) and am writing on behalf of
the Company in response to the letter from the Staff of the Division of Corporation Finance (the &ldquo;<U>Staff</U>&rdquo;),
of the U.S. Securities and Exchange Commission, dated December 2, 2019 (the &ldquo;<U>Comment Letter</U>&rdquo;) relating to the
above-referenced Form 10-K for the Fiscal Year Ended December 31, 2018 (the &ldquo;<U>Form 10-K</U>&rdquo;). Set forth below is
the Company&rsquo;s response to the comment raised in the Comment Letter. For the convenience of the Staff, the comments in the
Comment Letter are reprinted in bold and is followed by the Company&rsquo;s response.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Note
5 Derivative Liabilities, page F-14</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>1.
We read your response to comment 3. It appears your warrants meet the definition of a derivative; however, please provide us with
your analysis of whether the warrants should be classified as a liability or equity. Refer to guidance in ASC 805-40-25.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Response</U>:
The warrants should be classified as a liability. On our existing filings, we classified the derivatives as liabilities. The analysis
is that: We determined that the derivatives should be classified as liabilities per ASC 805-40-25, because they represent additional
value that may need to be issued to the holder of the warrant &ndash; which is a liability to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
cashless exercise feature of our warrants requires the Company to issue shares of its common stock on conversion of the warrants
based on either the average closing price of the shares as quoted over the last 30 trading days prior to the conversion or if
exercised in connection with an initial public offering the per share value will be the higher of the fair market value or the
per share price offered at the public offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Should
the Staff have additional questions or comments regarding the foregoing or the Form 10-K, please contact me at (310) 766-6223.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
truly yours,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alexander
    K. Arrow, MD</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cc:</FONT></TD>
    <TD STYLE="width: 95%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kenneth
    S. Goodwin (ksg@msf-law.com)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo_001.jpg
<TEXT>
begin 644 logo_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !4 -8# 2(  A$! Q$!_\0
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M<RO:YI44458PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#F!PI_'%==-/';VTEQ(V(XT+L<= !DUE:U<:#HFE"?58;:*R5@@!@W*">@P
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9BB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
